First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD StudyEduardo Díaz‐Rubio, Auxiliadora Gómez‐España, Bartomeu Massutí et al.|The Oncologist|2012Cited by 213
Irinotecan in Combination With Fluorouracil in a 48-Hour Continuous Infusion As First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors StudyJavier Sastre, Eduardo Díaz‐Rubio, Eugenio Marcuello et al.|Journal of Clinical Oncology|2005Cited by 98
Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors StudyJavier Sastre, Eduardo Díaz‐Rubio, M.L. Maestro et al.|The Oncologist|2012Cited by 88
Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transitionLuís Antón Aparicio, Angélica Figueroa, Vanessa Abella et al.|Cellular and Molecular Life Sciences|2013Cited by 54
Clinical implications of epithelial cell plasticity in cancer progressionLuís Antón Aparicio, Angélica Figueroa, M. Blanco et al.|Cancer Letters|2015Cited by 49